Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBITDA Margin (2023 - 2025)

Kura Oncology (KURA) has disclosed EBITDA Margin for 3 consecutive years, with 466.62% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 532245.0% to 466.62% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 412.56% through Dec 2025, down 1103319.0% year-over-year, with the annual reading at 412.56% for FY2025, 9345.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 466.62% at Kura Oncology, down from 356.19% in the prior quarter.
  • The five-year high for EBITDA Margin was 12821.6% in Q3 2024, with the low at 466.62% in Q4 2025.
  • Average EBITDA Margin over 3 years is 6533.74%, with a median of 8955.09% recorded in 2023.
  • The sharpest move saw EBITDA Margin surged 368423bps in 2024, then crashed -1317779bps in 2025.
  • Over 3 years, EBITDA Margin stood at 10284.77% in 2023, then plummeted by -53bps to 4855.83% in 2024, then tumbled by -110bps to 466.62% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 466.62%, 356.19%, and 434.23% for Q4 2025, Q3 2025, and Q2 2025 respectively.